Olanzapine

May be taken with or without food.

Patient w/ angle-closure glaucoma.

Patient w/ cerebrovascular disease or conditions predisposing to hypotension, benign prostatic hyperplasia, paralytic ileus, DM, Parkinson's disease, history of blood dyscrasias, bone marrow depression, hypereosinophilic disorders, myeloproliferative disease, history of seizures or conditions that lower the seizure threshold. IM: Acute MI, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery. Elderly w/ dementia-related psychosis. Hepatic and renal impairment. Pregnancy and lactation. Patient Counselling This drug may cause somnolence and dizziness, if affected, avoid driving and operating machinery. Avoid cigarette smoking. Monitoring Parameters Monitor BP, pulse and resp rate for at least 4 hr after IM inj. Clinical monitoring for hyperglycaemia, plasma lipids and wt.

Somnolence, wt gain, hyperprolactinaemia, increased appetite, dizziness, fatigue, elevated plasma glucose, triglyceride and liver enzyme values, oedema, orthostatic hypotension, constipation, dry mouth; agranulocytosis, eosinophilia, leucopenia, neutropenia, thrombocytopenia; hypertriglyceridaemia, hypercholesterolaemia, bradycardia, arthralgia, sedation.
Potentially Fatal: Neuroleptic malignant syndrome, pancreatitis, stroke, transient ischaemic attack, status epilepticus, exacerbation of pre-existing diabetes sometimes leading to ketoacidosis or coma.

Increased olanzapine clearance w/ CYP1A2 inducers (e.g. carbamazepine, omeprazole). Inhibits metabolism w/ CYP1A2 inhibitors (e.g. fluvoxamine). May antagonise effects of levodopa and dopamine agonists. Reduced bioavailability w/ activated charcoal. Additive effect w/ centrally acting drugs or drugs known to increase QT interval.

Antipsychotics

N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics